Verbindungen und Pharmazeutische Zusammensetzungen davon zur Behandlung von Krankheiten

Details

Veröffentlichungs-Nr.

EP4751779

Anmeldetag

29. Mai 2019

Veröffentlichung

3. Juni 2026

Rechtsraum

EP

IPC

A61P37/00

Abstract

The present invention discloses compounds or acceptable salts thereof according to Formula I: <img class="EMIRef" id="55e2af13-00f9-419c-aea8-370ed4f68ede-ia01" /> for use in the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases, wherein R<1>, R<2a>, X, Y, and Z are as defined herein.

Anmelder

Firmen

Coultreon Biopharma BV
ONCO3R Therapeutics BV

Land

🇧🇪 Belgien

Fachgebiete